Publikationen

Acker F, Reck M, Martin D, Rieken S, Heinzen S, Rost M, Aguinarte L, Schulte H, Serve H, Oellerich T, Sebastian M, Althoff FC. Efficacy and safety of immune checkpoint inhibition combined with concurrent chemoradiotherapy in patients with stage III unresectable non-small cell lung cancer: A systematic review and meta-analysis. Eur J Cancer 2025;218:115266 (PubMed-Link).

Akiyama H, Yoshida K, Kotsuma T, Masui K, Takenaka T, Kano M, Isohashi F, Seo Y, Shimbo T, Murakami N, Mori Y, Kotaki S, Yoshimoto H, Tanaka E, Tselis N, Takácsi-Nagy Z, Yamazaki H, Nakamura S, Tanigawa N, Shimizutani K, Ogawa K, Ariji Y. Validity of High-Dose-Rate Interstitial Brachytherapy as Monotherapy for Mobile Tongue Cancer in Terms of the Acute Mucosal Reaction. Kurume Med J. 2024. epub ahead of print (PubMed-Link). 

Buhr CR, Ernst BP, Blaikie A, Smith H, Kelsey T, Matthias C, Fleischmann M, Jungmann F, Alt J, Brandts C, Kämmerer PW, Foersch S, Kuhn S, Eckrich J. Assessment of decision-making with locally run and web-based large language models versus human board recommendations in otorhinolaryngology, head and neck surgery. Eur Arch Otorhinolaryngol 2025; epub ahead of print (Pubmed-Link).

Diefenhardt M, Kosmala R, Fleischmann M, Martin D, Hofheinz RD, Ghadimi M, Rödel C, Polat B, Fokas E. Chemotherapy before or after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer: 5-year results of the CAO/ARO/AIO-12 trial - a general pairwise comparison. ESMO Open 2025;10(3):104483. Epub ahead of print (PubMed_Link).

Gaedcke J, Sahrhage M, Ebeling M, Azizian A, Rühlmann F, Bernhardt M, Grade M, Bechstein WO, Germer CT, Grützmann R, Piso P, Hofheinz RD, Staib L, Beißbarth T, Kosmala R, Fokas E, Rödel C, Ghadimi M Prognosis and quality of life in patients with locally advanced rectal cancer after abdominoperineal resection in the CAO/ARO/AIO-04 randomized phase 3 trial. Sci Rep 2025;15:5401 (Pubmed-Link).

Haydo A, Schmidt J, Crider A, Kögler T, Ertl J, Hoffmann ME, Hehlgans S, Rathore R, Güllülü Ö, Wang Y, Zhang X, Herold-Mende C, Pampaloni F, Tegeder I, Dikic I, Dai M, Rödel F, Kögel D, Linder B. BRAT1 - a new therapeutic target for glioblastoma. Cell Mol Life Sci 2025;82:52 (PubMed-Link).

Hehlgans S, Eckert D, Martin D, Lumniczky K, Bug G, Rödel C, Rödel F. Irradiation alters extracellular vesicle microRNA load in the serum of patients with leukaemia. Strahlenther Onkol 2025; 201:173-184 (Pubmed-Link).

Issing C, Menche C, Richter MR, Mosa MH H, von der Grün J, Fleischmann M, Thönissen P, Winkelmann R, Darvishi T, Loth AG, Ghanaati S, Rödel F, Wild PJ, Brandts CH, Stöver T, Farin HF. Head and Neck Tumor Organoid Biobank for Modelling Individual Therapy Responses according to the TP53/HPV status. J Exp Clin Cancer Res. 2025;44:85 (PubMed-Link).

Licher J, Achenbach J, Köhn J, Diefenhardt M, Fleischmann M, Rödel C, Tselis N, Ramm U, Scherf C. Advantages of 3D Printed Patient-Individual Moulds in Brachytherapy for Facial Skin Cancer. Strahlenther Oncol 2025; epub ahead of print (PubMed-Link).

Moustakis C, Blanck O, Grohmann M, Albers D, Bartels D, Bathen B, Borzì GR, Broggi S, Bruschi A, Casale M, Delana A, Doolan P, Ebrahimi Tazehmahalleh F, Fabiani S, Falco MD, Fehr R, Friedlein M, Gutser S, Hamada AM, Hancock T, Köhn J, Kornhuber C, Krieger T, Lambrecht U, Lappi S, Moretti E, Mirus A, Muedder T, Plaude S, Polvika B, Ravaglia V, Righetto R, Rinaldin G, Schachner H, Scaggion A, Schilling P, Szeverinski P, Villaggi E, Walke M, Wilke L, Winkler P, Nicolay NH, Eich HT, Gkika E, Brunner TB, Schmitt D. Planning Benchmark Study for Stereotactic Body Radiation Therapy of Pancreas Carcinomas With Simultaneously Integrated Boost and Protection: Results of the DEGRO/DGMP Working Group on Stereotactic Radiation Therapy and Radiosurgery. Int J Radiat Oncol Biol Phys 2025;121:547-557 (Pubmed-Link)

Rödel F, Fleischmann M, Diefenhardt M, Dapper H, Hoffmann A, Rödel C, Martin D, Fokas E. Emerging advances and future opportunities in the molecular and therapeutic landscape of anal cancer. Nat Rev Clin Oncol 2025 accepted (Pubmed-Link)

Williams H, Fokas E, Diefenhardt M, Lee C, Verheij FS, Omer DM, Lin ST, Dunne RF, Marcet J, Cataldo P, Polite B, Piso P, Polat B, Dapper H, Ghadimi M, Hofheinz RD, Qin LX, Saltz LB, Wu AJ, Gollub MJ, Smith JJ, Weiser MR, Rödel C, Garcia-Aguilar J. Survival Among Patients Treated with Total Mesorectal Excision or Selective Watch-and-Wait After Total Neoadjuvant Therapy: A Pooled Analysis of the CAO/ARO/AIO-12 and OPRA Randomized Phase II Trials. Ann Oncol 2025; epub ahead of print (Pubmed-Link).

Brekner MC, Imhoff D, Rödel C, Filmann N, Licher J, Ramm U, Köhn J. Stereotactic body radiotherapy with volumetric intensity-modulated arc therapy and flattening filter-free beams: dosimetric considerations. Strahlenther Onkol 2024;200:346-357. (Pubmed-Link)

Diefenhardt M, Martin D, Hofheinz RD, Ghadimi M, Fokas E, Rödel C, Fleischmann M. Persistent Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Rectal Cancer. JAMA Netw Open 2024;7:e2432927 (Pubmed-Link).

Diefenhardt M, Martin D, Fleischmann M, Hofheinz RD, Ghadimi M, Rödel C, Fokas E. Tumor Response and Its Impact on Treatment Failure in Rectal Cancer: Does Intensity of Neoadjuvant Treatment Matter? Cancers (Basel) 2024;16:3673 (PubMed-Link)

Fokas E, Williams H, Diefenhardt M, Lin S, Qin LX, Piso P, Dapper H, Germer CT, Grützmann R, Tim Friede J, Joshua Smith J, Saltz LB, Wu AJ, Weiser MR, Omer D, Ghadimi M, Hofheinz RD, Garcia-Aguilar J, Rödel C; German Rectal Cancer Study Group and the OPRA ConsortiumChemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: Pooled analysis of the CAO/ARO/AIO-12 and the OPRA randomized phase 2 trials. Eur J Cancer 2024;210:114291. (PubMed Link)

Fokas E, Smith JJ, Garcia-Aguilar J, Glynne-Jones R, Buyse M, Rödel C. Early Efficacy End Points in Neoadjuvant Rectal Cancer Trials: Surrogacy Revisited. J Clin Oncol 2024;42:872-875. Commentary (PubMed-Link)

Haderlein M, von der Grün J, Balermpas P, Rödel C, Hautmann MG, Steger F, Bohr C, Hehr T, Stromberger C, Budach V, Schymalla M, Engenhart-Cabillic R, Kocik L, Geinitz H, Nestle U, Klautke G, Scherl C, Gall C, Frey B, Schubert P, Semrau S, Ott O, Kesting M, Iro H, Mueller SK, Fietkau R. De-intensification of postoperative radiotherapy in head and neck cancer irrespective of human papillomavirus status-results of a prospective multicenter phase II trial (DIREKHT Trial). Front Oncol. 2024;14:1447123 (Pubmed-Link).

Hecht M, Frey B, Gaipl US, Tianyu X, Eckstein M, Donaubauer AJ, Klautke G, Illmer T, Fleischmann M, Laban S, Hautmann MG, Tamaskovics B, Brunner TB, Becker I, Zhou JG, Hartmann A, Fietkau R, Iro H, Döllinger M, Gostian AO, Kist AM. Machine Learning-assisted immunophenotyping of peripheral blood identifies innate immune cells as best predictor of response to induction chemo-immunotherapy in head and neck squamous cell carcinoma - knowledge obtained from the CheckRad-CD8 trial. Neoplasia 2024;49:100953. epub ehead of print (Pubmed-Link)

Hofheinz RD, Herrle F, Dechow T, von Weikersthal LF, Welslau M, Lettmaier S, Burkart C, Kubicka S, Kochen L, Merx K, Krause K, Ebert M, Rödel C, Fokas E, Ghadimi M, Reissfelder C, Gaiser T mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214). ESMO Open 2024;9:103703 (Pubmed-Link).

Hofheinz RD, Arnold D, Borner M, Eisterer W, Folprecht G, Ghadimi M, Graeven U, Grünberger B, Hebart H, Hegewisch-Becker S, Heinemann V, Pritzkuleit R, Rödel C, Rumpold H, Trarbach T; Maschmeyer; Wörmann B. Guidelines: onkopedia - what´s new? Locally advanced rectal cancer. Oncol Res Treat 2024:1-9. epub ahead of print (Pubmed-Link).

Kagawa Y, Smith JJ, Fokas E, Watanabe J, Cercek A, Greten FR, Bando H, Shi Q, Garcia-Aguilar J, Romesser PB, Horvat N, Sanoff H, Hall W, Kato T, Rödel C, Dasari A, Yoshino T. Future direction of total neoadjuvant therapy for locally advanced rectal cancer. Nat Rev Gastroenterol Hepatol. 2024;21:444-455. (Pubmed-Link).

Khodabakhshi Z, Motisi L, Bink A, Broglie MA, Rupp NJ, Fleischmann M, von der Grün J, Guckenberger M, Tanadini-Lang S, Balermpas P. MRI-based radiomics for predicting histology in malignant salivary gland tumors: methodology and "proof of principle". Sci Rep 2024;14:9945 (Pubmed-Link).

König S, Strassheimer F, Brandner NI, Schröder J-H, Urban H, Harwart LF, Hehlgans S, Steinbach JP, Ronellenfitsch MW, Luger AS. Superoxide dismutase 1 mediates adaptation to the tumor microenvironment of glioma cells via mammalian target of rapamycin complex 1. Cell Death Discov 2024;10:379. (PubMed-Link).

Linge A, Patil S, Grosser M, Lohaus F, Gurtner K, Kemper M, Gudziol V, Haim D, Nowak A, Tinhofer I, Zips D, Guberina M, Stuschke M, Balermpas P, Rödel C, Schäfer H, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Belka C, Pigorsch S, Combs SE, Boeke S, Gani C, Jöhrens K, Baretton GB, Löck S, Baumann M, Krause M. The value of subcutaneous xenografts for individualised radiotherapy in HNSCC: robust gene signature correlates with radiotherapy outcome in patients and xenografts.  Radiother Oncol 2024:191:110055. (Pubmed-Link)

Martin D, Rödel F, Hehlgans S, Looso M, Ziegler PK, Fleischmann M, Diefenhardt M, Fries L, Kalinauskaite G, Tinhofer I, Zips D, Gani C, Rödel C, Fokas E. Inflammatory pathways confer resistance to chemoradiotherapy in anal squamous cell carcinoma. NPJ Precis Oncol 2024;8(1):93. (Pubmed-Link).

Maier SH, Schönecker S, Anagnostatou V, Garny S, Nitschmann A, Fleischmann DF, Büttner M, Kaul D, Imhoff D, Fokas E, Seidel C, Hau P, Kölbl O, Popp I, Grosu AL, Haussmann J, Budach W, Celik E, Kahl KH, Hoffmann E, Tabatabai G, Paulsen F, Holzgreve A, Albert NL, Mansmann U, Corradini S, Belka C, Niyazi M, Bodensohn R. Dummy run for planning of isotoxic dose-escalated radiation therapy for glioblastoma used in the PRIDE trial (NOA-28; ARO-2024-01; AG-NRO-06). Clin Transl Radiat Oncol. 2024;47:100790. (Pubmed-Link).

Rickel JK, Zeeb D, Knake S, Urban H, Konczalla J, Weber KJ, Zeiner PS, Pagenstecher A, Hattingen E, Kemmling A, Fokas E, Adeberg S, Wolff R, Sebastian M, Rusch T, Ronellenfitsch MW, Menzler K, Habermehl L, Möller L, Czabanka M, Nimsky C, Timmermann L, Grefkes C, Steinbach JP, Rosenow F, Kämppi L, Strzelczyk A. Status epilepticus in patients with brain tumors and metastases: A multicenter cohort study of 208 patients and literature review. Neurol Res Pract 2024;6:19. (Pubmed-Link).

Rühle A, Weymann M, Behrens M, Marschner S, Haderlein M, Fabian A, Senger C, Dickstein DR, Kraft J, von der Grün J, Chen E, Aquino-Michaels T, Domschikowski J, Bickel A, Altay-Langguth A, Kalinauskaite G, Lewitzki V, Bonomi M, Blakaj DM, Jhawar SR, Baliga S, Barve R, Ferentinos K, Zamboglou C, Schnellhardt S, Haehl E, Spohn SKB, Kuhnt T, Zöller D, Guckenberger M, Budach V, Belka C, Bakst R, Mayer A, Schmidberger H, Grosu AL, Balermpas P, Stromberger C, Nicolay NH. A Multicenter Evaluation of Different Chemotherapy Regimens in Older Adults With Head and Neck Squamous Cell Carcinoma Undergoing Definitive Chemoradiation. Int J Radiat Oncol Biol Phys. 2024 ;118:1282-1293 https://pubmed.ncbi.nlm.nih.gov/37914144/(Pubmed-Link).

Winkelmann R, Weißgerber M, Wild PJ, Bein J, Fleischmann M, Demes M, Balermpas P, Loth A, Bankov K, von der Grün J. Single Center Characterization of a Cohort of Salivary Gland Carcinomas. Life (Basel) 2024;14:1089. (Pubmed-Link)

Schuettfort G, Roether C, Berger A, Fokas E, Fraunholz I, Groh A, Haberl A, Khaykin P, Martin D, Roedel C, Vehreschild M, Stephan C. Differences in the course of CD4 and CD8 cells after chemoradiotherapy in PLWH with anal cancer. AIDS Res Hum Retroviruses 2024;40:198-203. (Pubmed-Link).

Arnold C, Toussaint A, Mantel F, Flentje M, Bratengeier K. Dosimetric evaluation of a spinal cord dose-limiting 3D-CRT technique for radiotherapy of spinal metastases. J Appl Clin Med Phys 2023;24:e14042. (Pubmed-Link).

Burger MC, Forster MT, Romanski A, Straßheimer F, Macas J, Zeiner PS, Steidl E, Herkt S, Weber KJ, Schupp J, Lun JH, Strecker MI, Wlotzka K, Cakmak P, Opitz C, George R, Mildenberger IC, Nowakowska P, Zhang C, Röder J, Müller E, Ihrig K, Langen KJ, Rieger MA, Herrmann E, Bönig H, Harter PN, Reiss Y, Hattingen E, Rödel F, Plate KH, Tonn T, Senft C, Steinbach JP, Wels WS. Intracranial injection of NK cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma. Neuro Oncol 2023;25:2058-2071. (Pubmed-Link).

Chatzikonstantinou G, Diefenhardt M, Fleischmann M, Meissner M, Scherf C, Trommel M, Ramm U, Rödel C, Tselis N, Licher J. Customized 3D-printed molds for high dose-rate brachytherapy in facial skin cancer: First clinical experience. J Dtsch Dermatol Ges 2023;21:35-41. (Pubmed-Link).

Diefenhardt M, Fleischmann M, Martin D, Hofheinz RD, Piso P, Germer CT, Hambsch P, Grützmann R, Kirste S, Schlenska-Lange A, Ghadimi M, Rödel C, Fokas E. Clinical outcome after total neoadjuvant treatment (CAO/ARO/AIO-12) versus intensified neoadjuvant and adjuvant treatment (CAO/ARO/AIO-04) A comparison between two multicenter randomized phase II/III trials. Radiother Oncol 2023;179:109455 (Pubmed-Link).

Diefenhardt M, Martin D, Fleischmann M, Hofheinz RD, Ghadimi M, Rödel C, Fokas E. Overall Survival After Treatment Failure Among Patients With Rectal Cancer. JAMA Netw 2023;6:e2340256. (Pubmed-Link)

Divé I, Weber KJ, Hartung TI, Steidl E, Wagner M, Hattingen E, Franz K, Fokas E, Ronellenfitsch MW, Herrlinger U, Harter PN, Steinbach JP. Gliomatosis cerebri (GC) growth pattern: A single-center analysis of clinical, histological, and molecular characteristics of GC and non-GC glioblastoma. Neurooncol Adv. 2023;5(1):vdad131. (Pubmed-Link)

Fleischmann M, Rödel C. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer.Strahlenther Onkol 2023;199:871-873 . (Pubmed-Link).

Fokas E, Glynne-Jones R, Fleischmann M, Piso P, Tselis N, Ghadimi M, Hofheinz RD, Rödel C. Radiotherapy dose escalation using endorectal brachytherapy in elderly and frail patients with rectal cancer unsuitable for surgery: Lessons from studies in fit patients and future perspectives. Cancer Treat Rev. 2023;112:102490. (Pubmed-Link).

Fokas E, Rödel C. Preoperative treatment of rectal cancer-Critical comments on the US-American PROSPECT trial. Strahlenther Onkol 2023;199(8):781-783. (Pubmed-Link).

Fokas E, Rödel C, Smith JJ, Garcia-Aguilar J, Buyse M, Glynne-Jones R. Disease-free survival as the endpoint in multimodal rectal cancer trials: have we got this right? Lancet Gastroenterol Hepatol 2023;8:962-964. (Pubmed-Link).

Fokas E, Smith JJ, Garcia-Aguilar J, Glynne-Jones R, Buyse M, Rödel C. Early Efficacy End Points in Neoadjuvant Rectal Cancer Trials: Surrogacy Revisited. J Clin Oncol 2023 :JCO2301196. (Pubmed-Link).

Gambacorta MA, Chiloiro G, Masciocchi C, Mariani S, Romano A, Gonnelli A, Gerard JP, Ngan S, Rödel C, Bujko K, Glynne-Jones R, van Soest J, Dekker A, Damiani A, Valentini V.pCR and 2-Year Disease-Free Survival: A Combination of the Two Endpoints as a New Classification for Locally Advanced Rectal Cancer Patients-An Updated Pooled Analysis of Eleven International Randomized Trials. Cancers 2023;15:3209. (Pubmed-Link).

Gkika E, Kostyszyn D, Fechter T, Moustakis C, Ernst F, Boda-Heggemann J, Sarria G, Dieckmann K, Dobiasch S, Duma MN, Eberle F, Kroeger K, Häussler B, Izaguirre V, Jazmati D, Lautenschläger S, Lohaus F, Mantel F, Menzel J, Pachmann S, Pavic M, Radlanski K, Riesterer O, Gerum S, Röder F, Willner J, Barczyk S, Imhoff D, Blanck O, Wittig A, Guckenberger M, Grosu AL, Brunner TB. Interobserver agreement on definition of the target volume in stereotactic radiotherapy for pancreatic adenocarcinoma using different imaging modalities. Strahlenther Onkol 2023;199:973-981. (Pubmed-Link).

Groener D, Schneider S, Baumgarten J, Happel C, Klimek K, Mader N, Nguyen Ngoc C, Wichert J, Mandel P, Tselis N, Grünwald F, Sabet A. Baseline [68Ga]Ga-PSMA-11 PET/CT before [177Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable Lesions. Cancers 2023;15:473. (Pubmed-Link).

Krug D, Imhoff D, Haidenberger A, Heßler N, Schäfer J, Huttenlocher S, Chatzikonstantinou G, Fürweger C, Ramm U, König IR, Chun F, Staehler M, Rödel C, Muacevic A, Vonthein R, Dunst J, Blanck O.Robotic stereotactic body radiotherapy for localized prostate cancer: final analysis of the German HYPOSTAT trial. Strahlenther Onkol 2023;199:565-573. (Pubmed-Link).

Mader N, Nguyen Ngoc C, Kirkgöze B, Baumgarten J, Groener D, Klimek K, Happel C, Tselis N, Chun FKH, Grünwald F, Sabet A. Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 2023;50:1811-1821. (Pubmed-Link).

Mader N, Schoeler C, Pezeshkpour N, Klimek K, Groener D, Happel C, Tselis N, Mandel P, Grünwald F, Sabet A. Intermittent Radioligand Therapy with 177Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer. Cancers;2023;17;15:4605. (Pubmed-Link)

O'Cathail SM, Adams R, Hawkins MA, Sebag-Montefiore D, Marijnen CAM, Fokas E. Patient-reported outcomes in PROSPECT trial (Alliance N1048) - FOLFOX is not a panacea. Clin Transl Radiat Oncol. 2023;43:100672. (Pubmed-Link).

Sebag-Montefiore D, Cervantes A, Rodel C. Preoperative Treatment of Locally Advanced Rectal Cancer. N Engl J Med 2023;389:1631. (Pubmed-Link)

Spohn SKB, Draulans C, Kishan AU, Spratt D, Ross A, Maurer T, Tilki D, Berlin A, Blanchard P, Collins S, Bronsert P, Chen R, Pra AD, de Meerleer G, Eade T, Haustermans K, Hölscher T, Höcht S, Ghadjar P, Davicioni E, Heck M, Kerkmeijer LGW, Kirste S, Tselis N, Tran PT, Pinkawa M, Pommier P, Deltas C, Schmidt-Hegemann NS, Wiegel T, Zilli T, Tree AC, Qiu X, Murthy V, Epstein JI, Graztke C, Gao X, Grosu AL, Kamran SC, Zamboglou C. Genomic classifiers in personalized prostate cancer radiotherapy approaches - a systematic review and future perspectives based on international consensus. Int J Radiat Oncol Biol Phys 2023;116:503-520. (Pubmed-Link).

Sherry AD, Msaouel P, McCaw ZR, Abi Jaoude J, Hsu EJ, Kouzy R, Patel R, Yang Y, Lin TA, Taniguchi CM, Rödel C, Fokas E, Tang C, Fuller CD, Minsky B, Meirson T, Sun R, Ludmir EB. Prevalence and implications of significance testing for baseline covariate imbalance in randomised cancer clinical trials. Eur J Cancer 2023;194:113357. (Pubmed-Link).

Rembielak A, Mansy G, Barnes EA, Licher J, Tselis N. Advances in Skin Brachytherapy: Cosmesis and Function Preservation.Clin Oncol (R Coll Radiol) 2023;35:507-515. (Pubmed-Link).

Rödel F, Gaipl U. Future prospects in radiation oncology from the perspective of innovative radiation biology.  Strahlenther Onkol 2023;199:1077-1079. (Pubmed-Link)

Rösch J, Oertel M, Wegen S, Trommer M, Schleifenbaum J, Hering D, Mäurer M, Dobiasch S, Waltenberger M, von der Grün J, Medenwald D, Süß C, Hoeck M, Käsmann L, Fleischmann DF, Rühle A, Nicolay NH, Fabian A, Löser A, Heß S, Tamaskovics B, Vinsensia M, Hecht M. Dose-escalated re-irradiation improves outcome in locally recurrent head and neck cancer – Results of a large multicenter analysis. Radiother Oncol 2023;181:109380. (Pubmed-Link).

Rühle A, Marschner S, Haderlein M, Fabian A, Weymann M, Behrens M, Senger C, Dickstein DR, Kraft J, von der Grün J, Chen E, Aquino-Michaels T, Domschikowski J, Bickel A, Altay-Langguth A, Kalinauskaite G, Lewitzki V, Ferentinos K, Zamboglou C, Schnellhardt S, Haehl E, Spohn SKB, Gkika E, Zöller D, Guckenberger M, Budach V, Belka C, Bakst R, Mayer A, Schmidberger H, Grosu AL, Balermpas P, Stromberger C, Nicolay NH. Evaluation of Concomitant Systemic Treatment in Older Adults With Head and Neck Squamous Cell Carcinoma Undergoing Definitive Radiotherapy. JAMA Netw Open 2023;6:e230090. (Pubmed-Link).

Tawk B, Rein K, Schwager C, Knoll M, Wirkner U, Hörner-Rieber J, Liermann J, Kurth I, Balermpas P, Roedel C, Linge A, Loeck S, Lohaus F, Tinhofer I, Krause M, Stuschke M, Grosu AL, Zips D, Combs SE, Belka C, Stenzinger A, Herold-Mende C, Baumann M, Schirmacher P, Debus J, Abdollahi ADNA-Methylome based Tumor Hypoxia Classifier Identifies HPV-negative Head & Neck Cancer Patients at Risk for Locoregional Recurrence After Primary Radiochemotherapy. Clin Cancer Res 2023;29:3051-3064. (Pubmed-Link).

Viktorsson K, Rieckmann T, Fleischmann M, Diefenhardt M, Hehlgans S, Rödel F. Advances in Molecular Targeted Therapies to Increase Efficacy of (Chemo)Radiation Therapy. Strahlenther Onkol 2023;199:1091-1109. (Pubmed-Link).

Wenzel M, Garcia CC, Hoeh B, Jorias C, Humke C, Koll F, Tselis N, Rödel C, Graefen M, Tilki D, Chun FKH, Mandel P. Real-world evidence of outcomes of oligometastatic hormone-sensitive prostate cancer patients treated with metastasis-directed therapy. Prostate 2023;83(14):1365-1372.(Pubmed-Link)

Yoshida K, Kotsuma T, Takaoka Y, Tamenaga S, Yamazaki H, Nose T, Murakami N, Inaba K, Akiyama H, Masui K, Takenaka T, Kubota H, Tselis N, Masuda N, Yasojima H, Takeda M, Mano M, Nakamura S, Utsunomiya K, Tanigawa N, Tanaka E. HDR-brachytherapy for accelerated partial breast irradiation: Long-term experience from a Japanese institution. J Contemp Brachytherapy 2023;15:1-8. (Pubmed-Link).

Akiyama H, Yoshida K, Takenaka T, Kotsuma T, Masui K, Monzen H, Sumida I, Tsujimoto Y, Miyao M, Okumura H, Shimbo T, Takegawa H, Murakami N, Inaba K, Kashihara T, Takácsi-Nagy Z, Tselis N, Yamazaki H, Tanaka E, Nihei K, Ariji Y. Effect of a lead block on alveolar bone protection in image-guided high-dose-rate interstitial brachytherapy for tongue cancer: using model-based dose calculation algorithms to correct for inhomogeneity. J Contemp Brachytherapy 2022;14:87-95. (Pubmed-Link).

Baumgarten J, Groener D, Nguyen Ngoc C, Mader N, Chaurasia M, Davis K, Wichert J, Chun FKH, Tselis N, Happel C, Grünwald F, Sabet A. Safety and Efficacy of 177Lutetium-PSMA-617 Radioligand Therapy Shortly after Failing 223Radium-Dichloride. Cancers. 2022;14:557. (Pubmed-Link).

Beck M, Hartwich J, Eckstein M, Schmidt D, Gostian AO, Müller S, Rutzner S, Gaipl US, von der Grün J, Illmer T, Hautmann MG, Klautke G, Döscher J, Brunner T, Tamaskovics B, Hartmann A, Iro H, Kuwert T, Fietkau R, Hecht M, Semrau S. F18-FDG PET/CT imaging early predicts pathologic complete response to induction chemoimmunotherapy of locally advanced head and neck cancer: preliminary single-center analysis of the checkrad-cd8 trial. Ann Nucl Med 2022;36:623-633. (Pubmed-Link).

Berglar I, Hehlgans S, Wehle A, Roth C, Herold-Mende C, Rödel F, Kögel D, Linder B. CHRDL1 regulates stemness in glioma stem-like cells. Cells 2022;11:3917. (Pubmed-Link).

Chatzikonstantinou G, Wolff R, Tselis N. Fractionated stereotactic radiotherapy as a primary or salvage treatment for large brainstem metastasis. J Cancer Res Ther 2022;18:1604-1609. (Pubmed-Link).

Conradi LC, Rödel C, Ghadimi M. Rectal Cancer: Open Questions in 2022 Current Standards of Clinical Practice and Ongoing Trials. Digestion 2022;103:175-182. (Pubmed-Link).

Dapper H, Belka C, Bock F, Budach V, Budach W, Christiansen H, Debus J, Distel L, Dunst J, Eckert F, Eich H, Eicheler W, Engenhart-Cabillic R, Fietkau R, Fleischmann DF, Frerker B, Giordano FA, Grosu AL, Herfarth K, Hildebrandt G, Kaul D, Kölbl O, Krause M, Krug D, Martin D, Matuschek C, Medenwald D, Nicolay NH, Niewald M, Oertel M, Petersen C, Pohl F, Raabe A, Rödel C, Rübe C, Schmalz C, Schmeel LC, Steinmann D, Stüben G, Thamm R, Vordermark D, Vorwerk H, Wiegel T, Zips D, Combs SE. Integration of radiation oncology teaching in medical studies by German medical faculties due to the new licensing regulations: An overview and recommendations of the consortium academic radiation oncology of the German Society for Radiation Oncology (DEGRO). Strahlenther Onkol 2022:198:1-11. (Pubmed-Link).

Deloch L, Hehlgans S, Rückert M, Maier A, Hinrichs A, Flohr AS, Eckert D, Weissmann T, Seeling M, Nimmerjahn F, Fietkau R, Rödel F, Fournier C, Frey B, Gaipl US. Radon improves clinical response in an animal model of rheumatoid arthritis accompanied by increased numbers of peripheral blood B cells and Interleukin-5 concentration.Cells 2022;11:689. (Pubmed-Link).

Diefenhardt M, Schlenska-Lange A, Kuhnt T, Kirste S, Piso P, Bechstein WO, Hildebrandt G, Ghadimi M, Hofheinz RD, Rödel C, Fokas E. Total Neoadjuvant Therapy for Rectal Cancer in the CAO/ARO/AIO-12 Randomized Phase 2 Trial: Early Surrogate Endpoints Revisited. Cancers 2022;14:3658. (Pubmed-Link).

Diefenhardt M, Martin D, Ludmir EB, Fleischmann M, Hofheinz RD, Ghadimi M, Kosmala R, Polat B, Friede T, Minsky BD, Rödel C, Fokas E. Development and Validation of a Predictive Model for Toxicity of Neoadjuvant Chemoradiotherapy in Rectal Cancer in the CAO/ARO/AIO-04 Phase III Trial. Cancers 2022;14:4425. (Pubmed-Link).

Eckert D, Rapp F, Tsedeke AT, Molendowska J, Lehn R, Langhans M, Fournier C, Rödel F, Hehlgans S. ROS- and Radiation Source-Dependent Modulation of Leukocyte Adhesion to Primary Microvascular Endothelial Cells. Cells 2022;11:72. (Pubmed-Link).

Elwakeel E, Brüggemann M, Wagih J, Lityagina O, Elewa MAF, Han Y, Froemel T, Popp R, Nicolas AM, Schreiber Y, Gradhand E, Thomas D, Nüsing R, Steinmetz-Späh J, Savai R, Fokas E, Fleming I, Greten FR, Zarnack K, Brüne B, Weigert A. Disruption of prostaglandin E2 signaling in cancer-associated fibroblasts limits mammary carcinoma growth but promotes metastasis. Cancer Res 2022;82:1380-1395. (Pubmed-Link).

Emons G, Auslander N, Jo P, Kitz J, Azizian A, Hu Y, Hess CF, Roedel C, Sax U, Salinas G, Stroebel P, Kramer F, Beissbarth T, Grade M, Ghadimi M, Ruppin E, Ried T, Gaedcke J. Gene-expression profiles of pretreatment biopsies predict complete response of rectal cancer patients to preoperative chemoradiotherapy. Br J Cancer 2022;127:766-775. (Pubmed-Link).

Fleischmann M, Nicolas AM, Rödel F, Ghadimi M, Hofheinz RD, Greten FR, Rödel C, Fokas E. ACO/ARO/AIO-21 - Capecitabine-based Chemoradiotherapy in Combination with the IL-1 Receptor Antagonist Anakinra for Rectal Cancer Patients: A Phase I Trial of the German Rectal Cancer Study Group.  Clin Transl Radiat Oncol 2022;34:99-106. (Pubmed-Link).

Fleischmann M, Diefenhardt M, Trommel M, Scherf C, Ramm U, Chatzikonstantinou G, Fokas E, Rödel C, Tselis N. Image-guided high-dose-rate brachytherapy for rectal cancer: technical note and first clinical experience on an organ-preserving approach.Strahlenther Onkol 2022;198:654-662. (Pubmed-Link).

Fleischmann M, Diefenhardt M, Fokas E, Rödel C, Rödel F. Molekulare Prädiktoren des Tumoransprechens auf eine Radiochemotherapie des Rektumkarzinoms. Der Onkologe 2022;28:118–125. (Pubmed-Link).

Fleischmann M, Mandal R, Kostova I, Raab M, Sanhaji M, Hehlgans S, Diefenhardt, Fokas E, Rödel C, Strebhardt K. Rödel F. Prognostic impact of caspase-8, CDK9 and phospho-CDK9 (Thr 186) expression in patients with uterine cervical cancer treated with definitive chemoradiation and brachytherapy. Cancers 2022;14:5500. (Pubmed-Link).

Fokas E, Schlenska-Lange A, Polat B, Klautke G, Grabenbauer GG, Fietkau R, Kuhnt T, Staib L, Brunner T, Grosu AL, Kirste S, Jacobasch L, Allgäuer M, Flentje M, Germer CT, Grützmann R, Hildebrandt G, Schwarzbach M, Bechstein WO, Sülberg H, Friede T, Gaedcke J, Ghadimi M, Hofheinz RD, Rödel C. Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. JAMA Oncol 2022;8:e215445. (Pubmed-Link).

Frey A, Martin D, D'Cruz L, Fokas E, Rödel C, Fleischmann M. C-Reactive Protein to Albumin Ratio as Prognostic Marker in Locally Advanced Non-Small Cell Lung Cancer Treated with Chemoradiotherapy. Biomedicines 2022;10(3):598. (Pubmed-Link).

Ghadimi M, Rödel C, Hofheinz R, Flebbe H, Grade M. The Multimodal Treatment of Rectal Cancer. Dtsch Arztebl Int 2022;119:570-580. (Pubmed-Link)

George R, Hehlgans S, Fleischmann M, Rödel C, Fokas E, Rödel F. Advances in nanotechnology-based platforms for survivin-targeted drug discovery. Expert Opin Drug Discov 2022;17:733-754. (Pubmed-Link).

Glatzer M, Tanderup K, Rovirosa A, Fokdal L, Ordeanu C, Tagliaferri L, Chargari C, Strnad V, Dimopoulos JA, Šegedin B, Cooper R, Nakken ES, Petric P, van der Steen-Banasik E, Lössl K, Jürgenliemk-Schulz IM, Niehoff P, Hermansson RS, Nout RA, Putora PM, Plasswilm L, Tselis N. Role of Brachytherapy in the Postoperative Management of Endometrial Cancer: Decision-Making Analysis among Experienced European Radiation Oncologists. Cancers 2022;14:906. (Pubmed-Link).

Hecht M, Eckstein M, Rutzner S, von der Grün J, Illmer T, Klautke G, Laban S, Hautmann MG, Brunner TB, Tamaskovics B, Hinke A, Zhou JG, Frey B, Donaubauer AJ, Becker I, Semrau S, Hartmann A, Balermpas P, Budach W, Gaipl US, Iro H, Gostian AO, Fietkau R. Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer. J Immunother Cancer 2022:e003747 (Pubmed-Link)

Hecht M, von der Grün J, Semrau S, Müller S, Weissmann T, Gaipl US, Iro H, Fietkau R, Gostian AO. Highlights der ASCO- und ESMO-Jahrestagungen 2021: Strahlentherapie von Kopf-Hals-Tumoren. HNO 2022;70:258-264HNO 2022;70:258-264. (Pubmed-Link)

Hess J, Unger K, Maihoefer C, Schüttrumpf L, Weber P, Sebastian Marschner S, Wintergerst L, Pflugradt U, Baumeister P, Walch A, Woischke C, Kirchner T, Werner M, Sörensen K, Baumann M, Tinhofer I, Combs S, Debus J, Schäfer H, Krause M,Linge A, Von der Grün J, Stuschke M, Zips D, Canis M, Lauber K, Ganswindt U, Henke M, Zitzelsberger H, Claus Belka C. Integration of p16/HPV DNA status with a 24-miRNA-defined molecular  phenotype improves clinically relevant stratification of head and neck cancer patients. Cancers 2022, accepted. (Pubmed-Link)

Hladek L, Bankov K, von der Grün J, Filmann N, Demes M, Vallo S, Wild PJ, Winkelmann R. Tumor-associated immune cell infiltrate density in penile squamous cell carcinomas. Virchows Arch 2022;480:1159-1169. (Pumed-Link)

Köksal M, Baumert J, Schoroth F, Scafa D, Koch D, Leitzen C, Sarria GR, Giordano FA, Chatzikonstantinou G, Schmeel LC. Lung sparing and ribcage coverage in total body irradiation delivered by helical tomotherapy. Eur J Med Res 2022;27:287. (Pubmed-Link).

Lambregts DMJ, Bogveradze N, Blomqvist LK, Fokas E, Garcia-Aguilar J, Glimelius B, Gollub MJ, Konishi T, Marijnen CAM, Nagtegaal ID, Nilsson PJ, Perez RO, Snaebjornsson P, Taylor SA, Tolan DJM, Valentini V, West NP, Wolthuis A, Lahaye MJ, Maas M, Beets GL, Beets-Tan RGH. Current controversies in TNM for the radiological staging of rectal cancer and how to deal with them: results of a global online survey and multidisciplinary expert consensus. Eur Radiol 2022;32:4991-5003. (Pubmed-Link).

Löck S, Linge A, Lohaus F, Ebert N, Gudziol V, Nowak A, Tinhofer I, Kalinauskaite G, Guberina M, Stuschke M, Balermpas P, von der Grün J, Grosu AL, Debus J, Ganswindt U, Belka C, Peeken JC, Combs SE, De-Colle C, Zips D, Baretton GB, Krause M, Baumann M; DKTK-ROG. Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC - hypothesis generation on a multicentre cohort of the DKTK-ROG. Radiother Oncol 2022;169:8-14.(Pubmed-Link).

Luger AL, König S, Samp PF, Urban H, Divé I, Burger MC, Voss M, Franz K, Fokas E, Filipski K, Demes MC, Stenzinger A, Sahm F, Reuss DE, Harter PN, Wagner S, Hattingen E, Wichert J, Lapa C, Fröhling S, Steinbach JP, Ronellenfitsch MW.Molecular matched targeted therapies for primary brain tumors-a single center retrospective analysis. J Neurooncol 2022;159:243-259. (Pubmed-Link).

Mahmood A, Bhuva N, Fokas E, Glynne-Jones R. Compliance to chemoradiation in squamous cell carcinoma of the anus. Cancer Treat Rev. 2022;106:102381. (Pubmed-Link).

Mandal R, Raab M, Rödel F, Krämer A, Kostova I, Peňa-Llopis S, Häupl B, Oellerich T, Gasimli K, Sanhaji M, Becker S, Strebhardt K. The non-apoptotic function of Caspase-8 in negatively regulating the CDK9 mediated Ser2 phosphorylation of RNA Polymerase II in cervical cancer. Cell Mol Life Sci 2022;79:597. (Pubmed-Link).

Martin D, Schreckenbach T, Ziegler P, Filmann N, Kalinauskaite G, Tinhofer I, Budach V, Gani C, Zips D, Schimek-Jasch T, Schäfer H, Grosu AL, Thomas E, Krause M, Dapper H, Combs S, Hoffmann C, Stuschke M, Walter F, Belka C, Kurth I, Hadiwikarta WW, Baumann M, Rödel C, Fokas E. Evaluation of prognostic factors after primary chemoradiotherapy of anal cancer: A multicenter study of the German Cancer Consortium - Radiation Oncology Group (DKTK-ROG). Radiother Oncol 2022;167:233-238. (Pubmed-Link).

Moustakis C, Blanck O, Chan M, Boda-Heggemann J, Andratschke N, Duma MN, Albers D, Bäumer C, Fehr R, Körber SA, Schmidhalter D, Alraun M, Baus WW, Beckers E, Dierl M, Droege S, Ebrahimi Tazehmahalleh F, Fleckenstein J, Guckenberger M, Heinz C, Henkenberens C, Hennig A, Köhn J, Kornhuber C, Krieger T, Loutfi-Krauss B, Mayr M, Oechsner M, Pfeiler T, Pollul G, Schöffler J, Tümmler H, Ullm C, Walke M, Weigel R, Wertman M, Wiehle R, Wiezorek T, Wilke L, Wolf U, Eich HT, Schmitt D. Planning benchmark study for SBRT of liver metastases: Results of the DEGRO/DGMP working group stereotactic radiotherapy and radiosurgery. Int J Radiat Oncol Biol Phys 2022;113:214-227. (Pubmed-Link).

Nicolas A, Pesic M, Engel E, Paul K. Ziegler P, Diefenhardt M, Kennel KB, Büttner F, Conche C, Petrocelli V, Elwakeel E, Weigert A, Zinoveva A, Fleischmann M, Häupl B, Karakütük C, Bohnenberger H, Mosa M, Kaderali L, Gaedcke J, Ghadimi M, Rödel F, Arkan MC, Oellerich T, Rödel C, Fokas E, Greten FR. Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer. Cancer Cell 2022;40:1-17. (Pubmed-Link).

Nicolas A, Pesic M, Rödel F, Fokas E, Greten FR. Preclinical orthotopic mouse model of rectal cancer and neoadjuvant therapy. STAR Protocol (Cell Press) 2022;3:101749. (Pubmed-Link).

Osong B, Masciocchi C, Damiani A, Bermejo I, Meldolesi E, Chiloiro G, Berbee M, Lee SH, Dekker A, Valentini V, Gerard JP, Rödel C, Bujko K, van de Velde C, Folkesson J, Sainato A, Glynne-Jones R, Ngan S, Brændengen M, Sebag-Montefiore D, van Soest J. Bayesian network structure for predicting local tumor recurrence in rectal cancer patients treated with neoadjuvant chemoradiation followed by surgery. Phys Imaging Radiat Oncol 2022;22:1-7. (Pubmed-Link).

Patil S, Tawk B, Grosser M, Lohaus F, Gudziol V, Kemper M, Nowak A, Haim D, Tinhofer I, Budach V, Guberina M, Stuschke M, Balermpas P, Rödel C, Schäfer H, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Belka C, Pigorsch S, Combs SE, Boeke S, Zips D, Baretton GB, Baumann M, Krause M, Löck S, Linge A; DKTK-ROG. Analyses of molecular subtypes and their association to mechanisms ofradioresistance in patients with HPV-negative HNSCC treated bypostoperative radiochemotherapy. Radiother Oncol 2022;167:300-307. (Pubmed-Link).

Patil S*, Linge A*, Hiepe H, Grosser M, Lohaus F, Gudziol V, Kemper M, Nowak A, Haim D, Tinhofer I, Budach V, Guberina M, Stuschke M, Balermpas P, von der Grün J, Schäfer H, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Belka C, Pigorsch S, Combs SE, Boeke S, Zips D, Jöhrens K, Baretton GB, Baumann M, Krause M, Löck S for the DKTK-ROG. Postoperative radiochemotherapy improves loco-regional control in a subset of patients with intermediate-risk head and neck squamous cell carcinoma (HNSCC): a matched pair analysis. Cancers 2022; accepted. (Pubmed Link).

Patil S, Linge A, Hiepe H, Grosser M, Lohaus F, Gudziol V, Kemper M, Nowak A, Haim D, Tinhofer I, Budach V, Guberina M, Stuschke M, Balermpas P, von der Grün J, Schäfer H, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Belka C, Pigorsch S, Combs SE, Boeke S, Zips D, Jöhrens K, Baretton GB, Baumann M, Krause M, Löck S. A Novel 2-Metagene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT. Cancers 2022;14(12),3031. (Pubmed-Link).

Rabasco Meneghetti A, Zwanenburg A, Linge A, Lohaus F, Grosser M, Baretton GB, Kalinauskaite G, Tinhofer I, Guberina M, Stuschke M, Balermpas P, von der Grün J, Ganswindt U, Belka C, Peeken JC, Combs SE, Böke S, Zips D, Troost EGC, Krause M, Baumann M, Löck S. Integrated radiogenomics analyses allow for subtype classification and improved outcome prognosis of patients with locally advanced HNSCC. Sci Rep 2022;12:16755. (Pubmed-Link).

Roesch J, Oertel M, Wegen S, Trommer M, Schleifenbaum J, Hering D, Mäurer M, Knippen S, Dobiasch S, Waltenberger M, von der Grün J, Medenwald D, Süß C, Hoeck M, Käsmann L, Fleischmann DF, Rühle A, Nicolay NH, Fabian A, Löser A, Heß S, Tamaskovics B, Vinsensia M, Hecht M. Dose-escalated re-irradiation improves outcome in locally recurrent head and neck cancer - Results of a large multicenter analysis. Radiother Oncol 2022:04502-9. (Pubmed-Link)

Scherf C, Ramm U, Stein T, Trommel M, Tselis N, Chatzikonstantinou G, Diefenhardt M, Rödel C, Köhn J, Licher J. Effects of iodinated contrast agent on HU-based dose calculation and dose delivered in iridium-192 high-dose-rate brachytherapy. J Contemp Brachytherapy 2022;14:80-86. (Pubmed-Link).

Shahzadi I, Zwanenburg A, Lattermann A, Linge A, Baldus C, Peeken JC, Combs SE, Diefenhardt M, Rödel C, Kirste S, Grosu AL, Baumann M, Krause M, Troost EGC, Löck S. Analysis of MRI and CT-based radiomics features for personalized treatment in locally advanced rectal cancer and external validation of published radiomics models. Sci Rep 2022;12:10192. (Pubmed-Link).

Sieker K, Fleischmann M, Trommel M, Ramm U, Licher J, Bug G, Martin H, Serve H, Rödel C, Balermpas P. Twenty years of experience of a tertiary cancer center in total body irradiation with focus on oncological outcome and secondary malignancies. Strahlenther Onkol 2022;198:547-557. (Pubmed-Link).

Schmid SC, Lewerich J, Retz M, Rödel C. Surgery only" is not enough: potential of multimodal therapy in urothelial bladder carcinoma.Urologie 2022;61:1332-1340. (Pubmed-Link).

Tandl D, Sponagel T, Fuck S, Smit T, Hehlgans S, Jacob B, Fournier C. Rödel F, Roth B, Moroni A, Alansary D, Niemeyer B, Thiel G. X-ray irradiation activates immune response in human T-lymphocytes via store-operated Ca2+ entry and NFAT activation .J Gen Physiol 2022;154:e202112865. (Pubmed-Link).

Tawk B, Wirkner U, Schwager C, Rein K, Zaoui K, Federspil PA, Adeberg S, Linge A, Ganswindt U, Hess J, Unger K, Tinhofer I, Budach V, Lohaus F, Krause M, Guberina M, Stuschke M, Balermpas P, Rödel C, Grosu AL, Schäfer H, Zips D, Combs SE, Pigorsch S, Zitzelsberger H, Baumeister P, Kirchner T, Bewerunge-Hudler M, Weichert W, Hess J, Herpel E, Belka C, Baumann M, Debus J, Abdollahi A, Tumor DNA-Methylome derived Epigenetic Fingerprint Identifies HPV-negative Head and Neck Patients at Risk for Locoregional Recurrence after Postoperative Radiochemotherapy. Int J Cancer 2022;150:603-616. (Pubmed-Link).

Tuzlakoğlu Öztürk M, Güllülü Ö. Dimerization underlies the aggregation propensity of intrinsically disordered coiled-coil domain-containing 124. Proteins 2022;90:218-228 (Pubmed-Link).

Von der Grün J, Rödel C, Semrau  S, Balermpas P, Martin D, Fietkau R, Haderlein M.  Patterns of care analysis for salivary gland cancer: a survey within the German Society of Radiation Oncology (DEGRO) and recommendations for the daily practice. Strahlenther Onkol 2022;198:123-134. (Pubmed-Link).

Von Der Grün J, Winkelmann R, Burck I, Martin D, Rödel F, Wild PJ, Bankov K, Weigert A, Kur IM, Brandts C, Filmann N, Issing C, Thönissen P, Tanneberger AM, Rödel C, Ghanaati S, Balermpas P. Neoadjuvant chemoradiotherapy for oral cavity cancer: Predictive factors for response and interim analysis of the prospective INVERT-Trial. Front Oncol 2022;12:817692. (Pubmed-Link).

Voss M, Wenger KJ, von Mettenheim N, Bojunga J, Vetter M, Diehl B, Franz K, Gerlach R, Ronellenfitsch MW, Harter PN, Hattingen E, Steinbach JP, Rödel C, Rieger J. Short-term fasting in glioma patients: analysis of diet diaries and metabolic parameters of the ERGO2 trial. Eur J Nutr 2022:61:477-487. (Pubmed-Link)

Wichtmann BD, Albert S, Zhao W, Maurer A, Rödel C, Hofheinz RD, Hesser J, Zöllner FG, Attenberger UI Are We There Yet? The Value of Deep Learning in a Multicenter Setting for Response Prediction of Locally Advanced Rectal Cancer to Neoadjuvant Chemoradiotherapy. Diagnostics 2022;12:1601. (Pubmed-Link).

Winkelmann R, Bankov K, von der Grün J, Cinatl J Jr, Wild PJ, Vallo S, Demes M. The routine use of LCD-Array hybridisation technique for HPV subtyping in the diagnosis of penile carcinoma compared to other methods. BMC Urol 2022;22:10. (Pubmed-Link).

Zeiner PS, Filipski K, Filmann N, Forster MT, Voss M, Fokas E, Herrlinger U, Harter PN, Steinbach JP, Ronellenfitsch MW. Sex-Dependent Analysis of Temozolomide-Induced Myelosuppression and Effects on Survival in a Large Real-life Cohort of Glioma Patients. Neurology 2022;98:e2073-e2083. (Pubmed-Link).

Zimmermann M, Richter A, Weick S, Exner F, Mantel F, Diefenhardt M, Fokas E, Kosmala R, Flentje M, Polat B. Acute toxicities of patients with locally advanced rectal cancer treated with intensified chemoradiotherapy within the CAO/ARO/AIO-12 trial: comparing conventional versus VMAT planning at a single center. Sci Rep 2022;12:21263. (Pubmed-Link).

Zoga E, Wolff R, Ackermann H, Meissner M, Rödel C, Tselis N, Chatzikonstantinou G. Factors Associated with Hemorrhage of Melanoma Brain Metastases after Stereotactic Radiosurgery in the Era of Targeted/Immune Checkpoint Inhibitor Therapies. Cancers 2022;14:2391. (Pubmed-Link).

Aigner F, Werner RN, Koswig S, Gaskins M, Rödel C, Kahlke V, Raab HR, Siegel R; die Leitliniengruppe Analkarzinom. Summary and comments on the S3 guideline on anal cancer: diagnostics, treatment and aftercare of anal canal and margin cancers. Chirurg 2021;92:244-247. (Pubmed-Link).

Altay-Langguth A, Balermpas P, Brandts C, Balster S, Ghanaati S, Winkelmann R, Burck I, Rödel F, Martin D, Rödel C, von der Grün J. Re-irradiation with concurrent and maintenance Nivolumab in locally recurrent and inoperable Squamous Cell Carcinoma of the Head and Neck: a single-center cohort study. Clin Transl Radiat Oncol 2021;28:71-78. (Pubmed-Link).

Arnold C, von der Grün J, Brekner M, Licher J, Fokas E, Rödel C, Fleischmann M. Risk stratification by anamnesis increases SARS-CoV-2 test efficiency in cancer patients. Strahlenther Onkol 2021;epub ahead of print. (Pubmed-Link)

Attenberger UI, Clasen S, Ghadimi M, Grosse U, Antoch G, Schreyer AG, Wessling J, Hausmann D, Piso P, Plodeck V, Stintzing S, Rödel CM, Hofheinz RD. Importance and Qualitative Requirements of Magnetic Resonance Imaging for Therapy Planning in Rectal Cancer - Interdisciplinary Recommendations of AIO, ARO, ACO and the German Radiological Society. Rofo 2021;193:513-520. (Pubmed-Link).

Behmüller M, Tselis N, Zamboglou N, Zoga E, Baltas D, Rödel C, Chatzikonstantinou G. High-Dose-Rate Brachytherapy as Monotherapy for Low- and Intermediate-Risk Prostate Cancer. Oncological Outcomes After a Median 15-Year Follow-Up. Front Oncol 2021;11:770959. (Pubmed-Link)

Chatzikonstantinou G, Scherf C, Köhn J, Ackermann H, Ramm U, Tselis N. Matched-pair dosimetric comparison of cardiac radiation exposure between deep-inspiration breath-hold whole-breast radiation therapy with Active Breathing Coordinator and interstitial multicatheter high-dose-rate brachytherapy as accelerated partial breast irradiation in adjuvant treatment of left-sided breast cancer after breast-conserving surgery.  Strahlenther Onkol. 2021;197:308-316. (Pubmed-Link).

Chatzikonstantinou G, Strouthos I, Scherf C, Köhn J, Solbach C, Rödel C, Tselis N. Interstitial multicatheter HDR-brachytherapy as accelerated partial breast irradiation after second breast-conserving surgery for locally recurrent breast cancer. J Radiat Res 2021:62:465-472. (Pubmed-Link).

Chatzikonstantinou G, Keller C, Scherf C, Bathen B, Köhn J, Tselis N. Real-world dosimetric comparison between CyberKnife SBRT and HDR brachytherapy for the treatment of prostate cancer. Brachytherapy 2021;20:44-49 (Pubmed-Link)

Corrigan KL, Kry S, Howell RM, Kouzy R, Jaoude JA, Patel RR, Jhingran A, Taniguchi C, Koong AC, McAleer MF, Nitsch P, Rödel C, Fokas E, Minsky BD, Das P, Fuller CD, Ludmir EB. The Radiotherapy Quality Assurance Gap Among Phase III Cancer Clinical Trials. Radiother Oncol 2021;166;51-57, (Pubmed-Link).

Czito B, Rödel C. Emerging Treatment Paradigms in Localized Rectal Cancer. Pract Radiat Oncol 2021;11:26-29. (Pubmed-Link).

Diefenhardt M, Chatzikonstantinou G, Meissner M, Köhn J, Scherf C, Trommel M, Licher J, Ramm U, Rödel C, Tselis N. HDR brachytherapy with individual epithetic molds for facial skin cancer: techniques and first clinical experience. Int J Dermatol 2021;60:717-723. (Pubmed-Link).

Diefenhardt M, Ludmir EB, Hofheinz RD, Ghadimi M, Minsky BD, Fleischmann M, Fokas E, Rödel C. Impact of body-mass index on treatment and outcome in locally advanced rectal cancer: A secondary, post-hoc analysis of the CAO/ARO/AIO-04 randomized phase III trial. Radiother Oncol 2021;164:223-231. (Pubmed-Link).

Divé I, Steidl E, Wagner M, Filipski K, Burger MC, Franz K, Harter PN, Bähr O, Fokas E, Herrlinger U, Steinbach JP. Gliomatosis Cerebri Growth Pattern: Association of Differential First-Line Treatment with Overall Survival in WHO Grade II and III Gliomas. Oncology 2021;99:215-224. (Pubmed-Link).

Fietkau R,·Grützmann R, Wittel U.A, Croner R.S, Jacobasch L,·Neumann U.P, Reinacher-Schick A, Imhoff D, Boeck S, Keilholz L, Oettle H, Hohenberger W.M, Golcher H, Bechstein W.O, Uhl W, Pirkl A, Adler W, Semrau S, Rutzner M, Ghadimi M, Lubgan D.R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007± trial. Strahlenther Onkol 2021;197:8-18. (Pubmed-Link).

Fleischmann M, Glatzer M, Rödel C, Tselis N. Radioimmunotherapy: future prospects from the perspective of brachytherapy. J Contemp Brachytherapy 2021;13:458-467. (Pubmed-Link)

Fleischmann M, Chatzikonstantinou G, Fokas E, Wichmann J, Christiansen H, Strebhardt K, Rödel C, Tselis N, Rödel F. Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer. Cancers 2021;13:5748. (Pubmed-Link)

Fokas E, Appelt A, Glynne-Jones R, Beets G, Perez R, Garcia-Aguilar J, Rullier E, Smith JJ, Marijnen C, Peters FP, van der Valk M, Beets-Tan R, Myint AS, Gerard JP, Bach SP, Ghadimi M, Hofheinz RD, Bujko K, Gani C, Haustermans K, Minsky BD, Ludmir E, West NP, Gambacorta MA, Valentini V, Buyse M, Renehan AG, Gilbert A, Sebag-Montefiore DS, Rödel C. International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. Nat Rev Clin Oncol 2021;18:805-816. (Pubmed-Link).

Gambacorta MA, Masciocchi C, Chiloiro G, Meldolesi E, Macchia G, van Soest J, Peters F, Collette L, Gérard JP, Ngan S, Rödel CC, Damiani A, Dekker A, Valentini V. Timing to achieve the highest rate of pCR after preoperative radiochemotherapy in rectal cancer: a pooled analysis of 3085 patients from 7 randomized trials. Radiother Oncol  2021;154:154-160. (Pubmed-Link).

Groener D, Nguyen CT, Baumgarten J, Bockisch B, Davis K, Happel C, Mader N, Nguyen Ngoc C, Wichert J, Banek S, Mandel P, Chun FKH, Tselis N, Grünwald F, Sabet A. Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. EJNMMI Res 2021;11(1):61. (Pubmed-Link)

Groener D, Baumgarten J, Haefele S, Happel C, Klimek K, Mader N, Nguyen Ngoc C, Tselis N, Chun FKH, Grünwald F, Sabet A. Salvage Radioligand Therapy with Repeated Cycles of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer with Diffuse Bone Marrow Involvement. Cancers 2021;13:4017. (Pubmed-Link).

Guberina M, Sak A, Pöttgen C, Tinhofer-Keilholz I, Budach V, Balermpas P, Von der Grün J, Rödel CM, Gikka E, Grosu AL, Abdollahi A, Debus J, Belka C, Pigorsch S, Combs S, Mönnich D, Zips D, De-Colle C, Welz S, Linge A, Lohaus F, Baretton G, Gauler T, Baumann M, Krause M, Schuler M, Bankfalvi A, Höing B, Lang S, Stuschke. MERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy. Pharmacogenomics J. 2021;21:37-46. (Pubmed-Link).

Güllülü Ö, Hehlgans S, Mayer BE, Gößner I, Petraki C, Hoffmann M, Dombrowsky MJ, Kunzmann P, Hamacher K, Strebhardt K, Fokas E, Rödel C, Münch C, Rödel F. A spatial and functional interaction of a heterotetramer Survivin-DNA-PKcs complex in DNA damage response. Cancer Res 2021;81:2304-2317. (Pubmed-Link).

Güllülü Ö, Hehlgans S, Rödel C, Fokas E, Rödel F. Tumor suppressor protein p53 and inhibitor of apoptosis proteins in colorectal cancer – a promising signalling network for therapeutic interventions. Cancers 2021;13:624. (Pubmed-Link).

Kirste S, Fokas E, Rödel C. Short-term radiotherapy with 5 × 5 Gy followed by preoperative chemotherapy and resection in patients with locally advanced rectal carcinoma results in improved disease-free survival. Strahlenther Onkol 2021;197:567-569.(Pubmed-Link).

Krug D, Hecht M, Ebert N, Mäurer M, Fleischmann DF, Fokas E, Straube C, Nicolay NH, Hörner-Rieber J, Schmitt D, von Neubeck C, Zamboglou C, Sperk E, Kaul D, Heß-Rieger J, Corradini S, Seidel C, Gani C, Baues C, Frey B, Blanck O, Gauer T, Niyazi M. Innovative radiation oncology Together - Precise, Personalized, Human : Vision 2030 for radiotherapy & radiation oncology in Germany. Strahlenther Onkol 2021;197:1043-1048. (Pubmed-Link)

Haak HE, Beets GL, Peeters K, Nelemans PJ, Valentini V, Rödel C, Kuo L, Calvo FA, Garcia-Aguilar J, Glynne-Jones R, Pucciarelli S, Suarez J, Theodoropoulos G, Biondo S, Lambregts DMJ, Beets-Tan RGH, Maas M. Prevalence of nodal involvement in rectal cancer after chemoradiotherapy. Br J Surg 2021;108:1251-1258. (Pubmed-Link)

Hecht M, Hahn D, Wolber P, Hautmann M G, Reichert D, Weniger S, Belka C, Bergmann T, Göhler T, Welslau M, Große-Thie C, Guntinas-Lichius O, von der Gruen J, Balermpas P, Orlowski K, Messinger D, Stenzel K G, Fietkau R. Prospective evaluation of radiotherapy with cetuximab and platinum-based chemotherapy with cetuximab in locally recurrent head and neck cancer. Cancers 2021;13:3413 (Pubmed-Link).

Kosmala R, Fokas E, Flentje M, Sauer R, Liersch T, Graeven U, Fietkau R, Hohenberger W, Arnold D, Hofheinz RD, Ghadimi M, Ströbel P, Staib L, Grabenbauer GG, Folprecht G, Kirste S, Uter W, Gall C, Rödel C, Polat B; of the German Rectal Cancer Study Group. Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO/ARO/AIO-04 phase 3 trial. Eur J Cancer 2021;144:281-290. (Pubmed-Link).

Lapa C, Nestle U, Albert NL, Baues C, Beer A, Buck A, Budach V, Bütof R, Combs SE, Derlin T, Eiber M, Fendler WP, Furth C, Gani C, Gkika E, Grosu AL, Henkenberens C, Ilhan H, Löck S, Marnitz-Schulze S, Miederer M, Mix M, Nicolay NH, Niyazi M, Pöttgen C, Rödel CM, Schatka I, Schwarzenboeck SM, Todica AS, Weber W, Wegen S, Wiegel T, Zamboglou C, Zips D, Zöphel K, Zschaeck S, Thorwarth D, Troost EGC. Value of PET imaging for radiation therapy. Strahlenther Onkol 2021;197;1-23. (Pubmed-Link).

Linder B, Schiesl A, Voss M, Rödel F, Hehlgans S, Güllülü Ö, Seifert V, Kögel D, Senft C, Dubinski D. Dexamethasone treatment limits efficacy of radiation, but does not interfere with glioma cell death induced by Tumor Treating Fields. Front Oncol 2021;11:715031 (Pubmed-Link)

Lumniczky K, Impens N, Armengol G, Candéias S, Georgakilas A, Hornhardt S, Martin O, Rödel F, Schaue D. Low dose ionizing radiation effects on the immune system. Environment Intern 2021;149:106212. (Pubmed-Link).

Mader N, Groener D, Tselis N, Banek S, Nagarajah J, Grünwald F, Sabet A. Outcome of 177Lu-PSMA-617 Radioligand Therapy in Chemo-Refractory Patients with Metastatic Castration-Resistant Early-Onset Prostate Cancer. Cancers 2021;13:4193. (Pubmed-LInk).

Niesel K, Schulz M, Anthes J, Alekseeva T, Macas J, Salamero-Boix A, Möckl A, Oberwahrenbrock T, Lolies M, Stein S, Plate KH, Reiss Y, Rödel F, Sevenich L. The immune suppressive microenvironment affects efficacy of radio-immunotherapy in brain metastasis. EMBO Mol Med 2021:13:e13412. (Pubmed-Link).

Niu M, Combs SE, Linge A, Krause M, Baumann M, Lohaus F, Ebert N, Tinhofer I, Budach V, von der Grün J, Rödel F, Grosu AL, Multhoff G. Comparison of the composition of lymphocyte subpopulations in non-relapse and relapse patients with squamous cell carcinoma of the head and neck before, during radiochemotherapy and in the follow-up period: a multicenter prospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiat Oncol 2021;16:141. (Pubmed-Link)

Obermüller T, Hautekiet J, Paula Busto M, Reynders D, Belgioia L, Cats A, Gilbert D, Koerber SA, Mai S, Meulendijks D, Rödel F, Yhim HY, Hetjens S, Weiß C, Rasmussen C, Urbute A, Verdoot F, Kjaer S, Reuschenbach M, Goetghebeur E, von Knebel Doeberitz M, Arbyn M, Prigge ES. Prognostic value of high-risk HPV DNA and p16INK4a immunohistochemistry in anal cancer patients: an individual patient data meta-analysis. Eur J Cancer 2021;157:165-178. (Pubmed-Link).

Pasalic D, Fuller CD, Mainwaring W, Lin TA, Miller AB, Jethanandani A, Espinoza AF, Grossberg AJ, Jagsi R, Das P, Koong AC, Rödel C, Fokas E, Thomas CR Jr, Minsky BD, Ludmir EB. Detecting the Dark Matter of Unpublished Clinical Cancer Studies: An Analysis of Phase 3 Randomized Controlled Trials.Mayo Clin Proc 2021;96:420-426. (Pubmed-Link)

Scherf C, Licher J, Mletzko C, Trommel M, Tselis N, Chatzikonstantinou G, Diefenhardt M, Rödel C, Köhn J, Ramm U. Individualized mould-based high-dose-rate brachytherapy for perinasal skin tumors: technique evaluation from a dosimetric point of view. J Contemp Brachytherapy 2021;13:179-187. (Pubmed-Link).

Semrau S, Gostian AO, Traxdorf M, Eckstein M, Rutzner S, von der Grün J, Illmer T, Hautmann M, Klautke G, Laban S, Brunner T, Tamaskovics B, Frey B, Zhou JG, Geppert CI, Hartmann A, Balermpas P, Budach W, Gaipl U, Iro H, Fietkau R, Hecht M. Implementation of Double Immune Checkpoint Blockade Increases Response Rate to Induction Chemotherapy in Head and Neck Cancer. Cancers 2021;13:1959. (Pubmed-Link).

Siegel R, Werner RN, Koswig S, Gaskins M, Rödel C, Aigner F. Anal Cancer-Diagnosis, Treatment and Follow-up. Dtsch Arztebl Int 2021;118:217-224. (Pubmed-Link).

Steidl E, Filipski K, Zeiner PS, Wagner M, Fokas E, Forster MT, Ronellenfitsch MW, Divé I, Steinbach JP, Harter PN, Bähr O. A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy. J Cancer Res Clin Oncol 2021;147:2373-2383. (Pubmed-Link).

Stera S, Miebach G, Buergy D, Dreher C, Lohr F, Wurster S, Rödel C, Marcella S, Krug D, Frank A G, Ehmann M, Fleckenstein J, Blanck O, Boda-Heggemann J. Liver SBRT with active motion compensation results in excellent local control for liver oligometastases: An outcome analysis of a pooled multi-platform patient cohort. Radiother Oncol 2021;158:230-236. (Pubmed-Link).

Von der Grün J, Winkelmann R, Rödel F, Balster S, Ghanaati S, Brandts C, Martin D, Rödel C, Kesar N, Balermpas P. Patterns of care, toxicity and outcome after treatment of salivary gland carcinomas: Long-term experience from a tertiary cancer center. Eur Arch Oto-Rhino-Laryngo 2021;278:4411-4421. (Pubmed-Link).

Voss M, Wenger KJ, Fokas E, Forster MT, Steinbach JP, Ronellenfitsch MW. Single-shot bevacizumab for cerebral radiation injury. BMC Neurol 2021;21:77. (Pubmed-Link).

Weissmann T, Speer S, Putz F, Lettmaier S,  Schubert P, Shariff M, Semrau S, Gostian AG, Traxdorf M, Sarina K Müller SK, Markus Eckstein M, Matthias Hautmann M, von der Grün J, Haderlein M, Frey B, Gaipl US, Bert C,  Iro H, Fietkau R, Hecht M. Reduction of elective radiotherapy treatment volume in definitive treatment of locally advanced head and neck cancer-comparison of a prospective trial with a revised contouring approach. J Clin Med 2021:10:4653  (Pubmed-Link).

Werner RN, Gaskins M, Avila Valle G, Budach V, Koswig S, Mosthaf FA, Raab HR, Rödel C, Nast A, Siegel R, Aigner F. State of the art treatment for stage I to III anal squamous cell carcinoma: a systematic review and meta-analysis. Radiother Oncol 2021:157:188-196. (Pubmed-Link).

Abi Jaoude J, Kouzy R, Mainwaring W, Lin TA, Miller AB, Jethanandani A, Espinoza AF, Pasalic D, Verma V, VanderWalde NA, Smith BD, Smith GL, Fuller CD, Das P, Minsky BD, Rödel C, Fokas E, Jagsi R, Thomas CR, Subbiah IM, Taniguchi CM, Ludmir EB. Performance Status Restriction in Phase III Cancer Clinical Trials. J Natl Compr Canc Netw. 2020;18:1322-1326. (Pubmed-Link).

Attenberger U, Rödel C, Ghadimi M, Piso P, Arnold D, Folprecht G, Geissler M, Hegewisch-Becker S, Heinemann V, Kasper S, Modest D, Reinacher-Schick A, Seufferlein T, Stein A, Stintzing S, Hofheinz RD. Prerequisites of magnetic resonance imaging for treatment planning in locally advanced rectal cancer - Interdisciplinary recommendations. Z Gastroenterol 2020;58:577-582. (Pubmed-Link).

Diefenhardt M, Ludmir EB, Hofheinz RD, Ghadimi M, Minsky BD, Rödel C, Fokas E. Association of Treatment Adherence With Oncologic Outcomes for Patients With Rectal Cancer: A Post Hoc Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial. JAMA Oncol 2020;6:1416-1421. (Pubmed-Link).

Fietkau R, Hecht M, Hofner B, Lubgan D, Iro H, Gefeller O, Rödel C, Hautmann MG, Kölbl O, Salay A, Rübe C, Melchior P, Breinl P, Krings W, Gripp S, Wollenberg B, Keerl R, Schreck U, Siekmeyer B, Grabenbauer GG, Balermpas P, PacCis-Study Group.. Randomized phase-III-trial of concurrent chemoradiation for locally advanced head and neck cancer comparing dose reduced radiotherapy with paclitaxel/cisplatin to standard radiotherapy with fluorouracil/cisplatin: The PacCis-trial, Radiother Oncol 2020;144:209-217. (Pubmed-Link).

Fokas E, Glynne-Jones R, Appelt A, Beets-Tan R, Beets G, Haustermans K, Marijnen C, Minsky BD, Ludmir E, Quirke P, Sebag-Montefiore D, Garcia-Aguilar J, Gambacorta MA, Valentini V, Buyse M, Rödel C. Outcome measures in multimodal rectal cancer trials. Lancet Oncol 2020 ;21:e252-e264. (Pubmed Link).

Freund I, Hehlgans S, Martin D, Ensminger M, Fokas E, Claus Rödel C, Löbrich M, Rödel F. Fractionation-dependent radiosensitization by molecular targeting of Nek1. Cells 2020;9:E1235. (Pubmed-Link).

Gaipl U, Multhoff G, Pockley G, Rödel F.  Editorial: Radioimmunotherapy—Translational Opportunities and Challenges. Front Oncol 2020;10:190. (Pubmed-Link).

Gambacorta MA, Masciocchi C, Chiloiro G, Meldolesi E, Macchia G, van Soest J, Peters F, Collette L, Gérard JP, Ngan S, Rödel C, Damiani A, Dekker A, Valentini V. Timing to achieve the highest rate of pCR after preoperative radiochemotherapy in rectal cancer: a pooled analysis of 3085 patients from 7 randomized trials. Radiother Oncol 2020;154:154-160 (Pubmed-Link).

Hecht M, Hahn D, Wolber P, Hautmann MG, Reichert D , Weniger S, Belka C, Bergmann T, Göhler T , Welslau M, Große-Thie C, Guntinas-Lichius O, von der Grün J, Balermpas P, Orlowski K, Messinger D, Karsten G. Stenzel KG, Fietkau R. Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer. BMC Cancer 2020;20:933. (Pubmed-Link).

Hecht M, Gostian AO, Eckstein M, Rutzner S, von der Grün J, Illmer T, Hautmann MG, Klautke G, Laban S, Brunner T, Hinke A, Becker I, Frey B, Semrau S, Geppert CI, Hartmann A, Balermpas P, Budach W, Gaipl US, Iro H, Fietkau R. Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8. J Immunother Cancer 2020;8:e001378. (Pubmed-Link).

Kesar N, Winkelmann R, Oppermann J, Ghanaati S, Neumayer T, Martin D, Rödel C, Rödel F, von der Grün J, Balermpas P. Prognostic impact of CD8-positive tumour-infiltrating lymphocytes and PD-L1 expression in salivary gland cancer. Oral Oncol 2020;111:104931. (Pubmed-Link).

Kosmala R, Fokas E, Flentje M, Sauer R, Liersch T, Graeven U, Fietkau R, Hohenberger W, Arnold D, Hofheinz RD, Ghadimi M, Ströbel P, Staib L, Grabenbauer GG, Folprecht G, Kirste S, Uter W, Gall C, Rödel C, Polat B. Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO/ARO/AIO-04 phase 3 trial. Eur J Cancer 2020;144:281-290. (Pubmed-Link).

Kouzy R, Abi Jaoude J, Mainwaring W, Lin TA, Miller AB, Jethanandani A, Espinoza AF, Verma V, Fuller CD, Minsky BD, Rödel C, Taniguchi CM, Ludmir EB. Professional Medical Writer Assistance in Oncology Clinical Trials.Oncologist 2020;25:e1812-e1815.(Pubmed-Link).

Leger S, Zwanenburg A, Leger K, Lohaus F, Linge A, Schreiber A, Kalinauskaite G, Tinhofer I, Guberina N, Guberina M, Balermpas P, von der Grün J, Ganswindt U, Belka C, Peeken JC, Combs SE, Boeke S, Zips D, Richter C, Krause M, Baumann M, Troost EG, Löck S. Comprehensive Analysis of Tumour Sub-Volumes for Radiomic Risk Modelling in Locally Advanced HNSCC. Cancers 2020;12:3047. (Pubmed-Link).

Ludmir EB, Fuller CD, Moningi S, Mainwaring W, Lin TA, Miller AB, Jethanandani A, Espinoza AF, Verma V, Smith BD, Smith GL, VanderWalde NA, Holliday EB, Guadagnolo BA, Stinchcombe TE, Jagsi R, Gomez DR, Minsky BD, Rödel C, Fokas E. Sex-Based Disparities Among Cancer Clinical Trial Participants. J Natl Cancer Inst 2020;112:211-213. (Pubmed-Link).

Maier A, Wiedemann J, Rapp F, Papenfuß F, Rödel F, Hehlgans S, Gaipl US, Kraft G, Fournier C, Frey B. Radon Exposure-Therapeutic Effect and Cancer Risk. Int J Mol Sci 2020;22:E316. (Pubmed-Link).

Martin D, Rödel F, von der Grün J, Rödel C, Fokas E. Acute organ toxicity correlates with better clinical outcome after chemoradiotherapy in patients with anal carcinoma. Radiother Oncol 2020;149:168-73. (Pubmed-Link).

Martin D, von der Grün J, Rödel C, Fokas E. Management of anal cancer patients - a pattern of care analysis in German-speaking countries. Radiat Oncol 2020;15:122. (Pubmed-Link).

Martin D, Rödel C, Fokas E. Influence of treatment compliance on the success of chemoradiotherapy for anal carcinoma. Strahlenther Onkol 2020;196:952-953. (Pubmed-Link).

Martin D, Balermpas P, Gollrad J, Weiß C, Valentini C, Stuschke M, Schäfer H, Henckenberens C, Debus J, Krug D, Kuhnt T, Brunner T, Bostel T, Engenhart-Cabillic R, Nestle U, Combs S, Belka C, Hautmann M, Hildebrandt G, Gani C, Polat B, Rödel C, Fokas E. RADIANCE - Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial. Clin Transl Radiat Oncol 2020;23:43-49. (Pubmed-Link).

Martin D, von der Grün J, Rödel C, Fokas E. Sarcopenia is associated with hematologic toxicity during chemoradiotherapy in patients with anal carcinoma. Frontiers in Oncology 2020;10:1576. (Pubmed-Link).

Marijnen CAM, Peters FP, Rödel C, Bujko K, Haustermans K, Fokas E, Glynne-Jones R, Valentini V, Spindler KG, Guren MG, Maignon P, Calvo FA, Pares O, Glimelius B, Sebag-Montefiore D. International expert consensus statement regarding radiotherapy treatment options for rectal cancer during the COVID 19 pandemic. Radiother Oncol 2020;148:213-215. (Pubmed-Link).

Michaelis M, Voges Y, Rothweiler F, Weipert F, von Deimling A, Westermann F, Rödel F, Wassa M, Cinatl J. Testing of the survivin suppressant YM155 in a large panel of drug-resistant neuroblastoma cell lines. Cancers 2020;12:E577. (Pubmed-Link).

Michaelis M, Wass M, Reddin I, Voges Y, Rothweiler F, Hehlgans S, Mernberger M, Nist A, Stiewe T, Rödel F, Cinatl J. Drug-adapted cancer cell lines reveal drug-induced heterogeneity and enable the identification of specific biomarkers for the acquired resistance setting, Cancers 2020;12:E1080. (Pubmed-Link).

Montero A, Sabater S, Rödel F, Gaipl US, Ott OJ, Seegenschmiedt MH, Arenas M Is it time to redefine the role of low-dose radiotherapy for benign disease? Ann Rheum Dis 2020;79:e34. (Pubmed-Link)

Multhoff G, Seier S, Stangl S, Sievert W, Shevtsov M, Werner C, Pockley AG, Blankenstein C, Hildebrandt M, Offner R, Ahrens N, Kokowski K, Hautmann M, Rödel C, Fietkau R, Lubgan D, Huber R, Hautmann H, Duell T, Molls M, Specht H, Haller B, Devecka M, Sauter A, Combs SE. Targeted Natural Killer Cell-Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial. Clin Cancer Res 2020;26:5368-537. (Pubmed-Link).

Nakata M, Yoshida K, Shimbo T, Yoshikawa N, Yoshioka H, Hori A, Sato C, Uesugi Y, Kogata Y, Masui K, Murakami N, Kashihara T, Akiyama H, Tselis N, Ohmichi M, Nihei K. High-dose-rate interstitial brachytherapy with hypoxic radiosensitizer KORTUC II for unresectable pelvic sidewall recurrence of uterine cervical cancer: a case report. J Contemp Brachytherapy 2020;12:606-611. (Pubmed-Link).

Pasalic D, McGinnis GJ, Fuller CD, Grossberg AJ, Verma V, Mainwaring W, Miller AB, Lin TA, Jethanandani A, Espinoza AF, Diefenhardt M, Das P, Subbiah V, Subbiah IM, Jagsi R, Garden AS, Fokas E, Rödel C, Thomas CR Jr, Minsky BD, Ludmir EB. Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials. Eur J Cancer 2020 ;136:176-185. (Pubmed-Link)

Rödel F, Arenas M, Ott O, Fournier C, Georgakilas AG, Tapio S, Trott KR, Gaipl US. Low-dose radiation therapy for COVID-19 pneumopathy: What are the evidences? Strahlenther Onkol 2020;196:679-682. (Pubmed-Link).

Rödel F, Zhou S, Győrffy B, Raab M, Sanhaji M, Mandal R, Becker S, Strebhardt K. The prognostic relevance of the proliferation markers Ki-67 and Plk1 in early-stage ovarian cancer patients with serous, low-grade carcinoma based on mRNA and protein expression. Front Oncol 2020;10:558932. (Pubmed-Link).

Röder F, Meldolesi E, Gerum S, Valentini V, Rödel C. Recent advances in (chemo-)radiation therapy for rectal cancer: a comprehensive review. Radiat Oncol 2020;15:262. (Pubmed-Link)

Schmid SC, Koll FJ, Rödel C, Maisch P, Sauter A, Beckert F, Seitz A, Kübler H, Flentje M, Chun F, Combs SE, Schiller K, Gschwend JE, Retz M. Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer - study protocol of a prospective, single arm, multicenter phase II trial (RACE IT). BMC Cancer 2020;20:8. (Pubmed-Link).

Schmidt S, Linge A, Großer M, Lohaus F, Gudziol V, Nowak A, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rödel C, Schäfer H, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Belka C, Pigorsch S, Combs SE, Mönnich D, Zips D, Baretton GB, Buchholz F, Baumann M, Krause M, Löck S; DKTK-ROG. Comparison of GeneChip, nCounter and real-time polymerase chain reaction based gene expressions predicting loco-regional tumour control after primary and postoperative radiochemo- therapy in head and neck squamous cell carcinoma. J Mol Diagn 2020;22:801-10. (Pubmed-Link).

Schmitt D, Blanck O, Gauer T, Fix MK, Brunner TB, Fleckenstein J, Loutfi-Krauss B, Manser P, Werner R, Wilhelm ML, Baus WW, Moustakis C. Technological quality requirements for stereotactic radiotherapy : Expert review group consensus from the DGMP Working Group for Physics and Technology in Stereotactic Radiotherapy.  Strahlenther Onkol 2020,196:421-43. (Pubmed-Link)

Schulz M, Michels B, Niesel K, Stein S, Farin H, Rödel F, Sevenich L. Cellular and molecular changes of brain metastases-associated myeloid cells during disease progression and therapeutic response. iScience 2020;23:101178. (Pubmed-Link).

Sprenger T, Beißbarth T, Sauer R, Tschmelitsch J, Fietkau R, Hohenberger W, Staib L, Raab HR, Rödel C, Ghadimi M. The long-term influence of hospital and surgeon volume on local control and survival in the randomized German Rectal Cancer Trial CAO/ARO/AIO-94. Surg Oncol 2020;35:200-205. (Pubmed-Link).

Starke S, Leger S, Zwanenburg A, Leger K, Lohaus F, Linge A, Schreiber A, Kalinauskaite G, Tinhofer I, Guberina N, Guberina M, Balermpas P, von der Grün J, Ganswindt U, Belka C, Peeken JC, Combs SE, Boeke S, Zips D, Richter C, Troost EGC, Krause M, Baumann M, Löck S. 2D and 3D convolutional neural networks for outcome modelling of locally advanced head and neck squamous cell carcinoma. Sci Rep 2020;10:15625. (Pubmed-Link).

Strouthos I, Tselis N, Ferentinos K, Karagiannis E, Milickovic N, Chatzikonstantinou G, Feder O, Zamboglou N. Intraluminal high-dose-rate brachytherapy - an alternative organ-preserving approach for primary male urothelial carcinoma with panurethral involvement. Pract Radiat Oncol 2020;10:e53-e56. (Pubmed-Link).

Unger K, Fleischmann DF, Ruf V, Felsberg J, Piehlmaier D, Samaga D, Hess J, Suresh MP, Mittelbronn M, Lauber K, Budach W, Sabel M, Rödel C, Reifenberger G, Herms J, Tonn JC, Zitzelsberger H, Belka C, Niyazi M. Improved risk stratification in younger IDH wild-type glioblastoma patients by combining a 4-miRNA signature with MGMT promoter methylation status. Neurooncol Adv 2020;2:vdaa137.(Pubmed-Link).

Valentini V, Marijnen C, Beets G, Bujko K, De Bari B, Cervantes A, Chiloiro G, Coco C, Gambacorta MA, Glynne-Jones R, Haustermans K, Meldolesi E, Peters F, Rödel C, Rutten H, van de Velde C, Aristei C. The 2017 Assisi Think Tank Meeting on rectal cancer: A positioning paper.Radiother Oncol 2020;142:6-16. (Pubmed-Link).

von der Grün J, Balermpas P. Radiotherapie mit Cetuximab oder Cisplatin beim Plattenepithelkarzinom der Kopf-Hals-Region – was ist zu bevorzugen? Strahlenther Onkol  2020;196:197-199. (Pubmed-Link).

Voss M, Wagner M, von Mettenheim N, Harter PN, Wenger KJ, Franz K, Bojunga J, Vetter M, Gerlach R, Glatzel M, Paulsen F, Hattingen E, Baehr O, Ronellenfitsch MW, Fokas E, Imhoff D, Steinbach JP, Rödel C, Rieger J. ERGO2: A prospective randomized trial of calorie restricted ketogenic diet and fasting in addition to re-irradiation for malignant glioma.Int J Radiat Oncol Biol Phys 2020;108:987-995. (Pubmed-Link).

Wenger KJ, Wagner M, Harter PN, Franz K, Bojunga J, Fokas E, Imhoff D, Rödel C, Rieger J, Hattingen E, Steinbach JP, Pilatus U, Voss M. Maintenance of Energy Homeostasis during Calorically Restricted Ketogenic Diet and Fasting-MR-Spectroscopic Insights from the ERGO2 Trial. Cancers 2020;12:E3549. (Pubmed-Link).

Wenzel M, Humke C, Wicker S, Mani J, Engl T, Hintereder G, Vogl TJ, Wild P, Köllermann J, Rödel C, Asgharie S, Theissen L, Welte M, Kluth LA, Mandel P, Chun FKH, Preisser F, Becker A. Movember health care initiative 2019: prostate cancer screening at the University Hospital Frankfurt. Urologe A 2020;59:1237-1245. (Pubmed-Link).

Diefenhardt M, Hofheinz RD, Martin D, Beissbarth T, Arnold D, Hartmann A, von der Grün J, Grützmann R, Liersch T, Ströbel P, Grabenbauer GG,  Rieger M, Fietkau R, Graeven U, Weitz J, Folprecht G, Ghadimi M, Rödel F, Rödel C, Fokas E. Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO-04 randomized phase 3 rectal cancer trial. Int J Cancer 2019;145:2282-2291. (Pubmed-Link).

Diefenhardt M, Ludmir EB, Hofheinz RD, Ghadimi M, Minsky BD, Rödel C, Fokas E. Association of sex with toxic effects, treatment adherence, and oncologic outcomes in the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 Phase 3 randomized clinical trials of rectal cancer. JAMA Oncol 2019;6:294-6. (Pubmed-Link).

Chae W, Schulz M, Niesel K, Klemm F, Joyce J, Prümmer M, Brill B, Bergs J, Rödel F, Pilatus U, Sevenich L. Evaluating therapeutic response of whole brain radiotherapy in a mouse model for breast-to-brain metastasis using magnetic resonance imaging and spectroscopy. Front Oncol 2019;9:1324 (Pubmed-Link).

Chatzikonstantinou G, Ulrich P, Archavlis E, Zamboglou N, Strouthos I, Zoga E, Baltas D, Tselis N. Interstitial high-dose-rate brachytherapy in the primary treatment of inoperable glioblastoma multiforme. J Contemp Brachytherapy 2019;11:215-220 (Pubmed-Link).

Chatzikonstantinou G, Zamboglou N, Baltas D, Ferentinos K, Bon D, Tselis N. Image-guided interstitial high-dose-rate brachytherapy for dose escalation in the radiotherapy treatment of locally advanced lung cancer: A single-institute experience. Brachytherapy 201918:829-834. (Pubmed-Link).

Eder T, Hess AK, Konschak R, Stromberger C, Jöhrens K, Fleischer V, Hummel M, Balermpas P, von der Grün J, Linge A, Lohaus F, Krause M, Baumann M, Stuschke M, Zips D, Grosu A, Abdollahi A, Debus J, Belka C, Pigorsch S, Combs S, Budach V, Tinhofer I. Interference of tumor mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: A multicenter retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Eur J Cancer. 2019;116:67-76. (Pubmed-Link).

Feczkó T, Piiper A, Pleli T, Schmithals C, Denk D, Hehlgans S, Rödel F, Vogl TJ, Wacker MG. Theranostic sorafenib-loaded polymeric nanocarriers manufactured by enhanced gadolinium conjugation techniques.  Pharmaceutics 2019,11:489. (Pubmed-Link).

Fleischmann M, Martin D, Peña-Llopis S, Oppermann J, von der Grün J, Diefenhardt M, Chatzikonstantinou G, Fokas E, Rödel C, Strebhardt K, Becker S, Rödel F, Tselis N. Association of Polo-like kinase 3 and phosphoT273 Caspase 8 with improved survival in patients with cervical squamous cell carcinoma treated with radical chemoradiotherapy and brachytherapy. Front Oncol 2019,9:742. (Pubmed-Link).

Fokas E, Allgäuer M, Polat B, Klautke G, Grabenbauer GG, Fietkau R, Kuhnt T, Staib L, Brunner T, Grosu AL, Schmiegel W,  Jacobasch L, Weitz J, Folprecht G, Schlenka-Lange A, Flentje M, Germer CT, Grützmann R, Schwarzbach M, Paolucci V, Bechstein WO, Friede T, Ghadimi M, Hofheinz RD, Rödel C, German Rectal Cancer Study Group. Randomized Phase II Trial on Chemoradiotherapy plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. J Clin Oncol 2019;37:3212-3222 (Pubmed-Link)

Gani C, Gani N, Zschaeck S, Eberle F, Schaeffeler N, Hehr T, Berger B, Fischer SG, Claßen J, Zipfel S, Rödel C, Teufel M, Zips D. Organ Preservation in Rectal Cancer: The Patients' Perspective .Front Oncol 2019;10;9:318. (Pubmed-Link).

Hausmann J, Kubesch A, von der Grün JM, Goettlich CM, Filmann N, Tal AO, Vermehren J, Friedrich-Rust M, Wächtershäuser A, Bojunga J, Blumenstein I. Prophylactic percutaneous endoscopic gastrostomy in patients with head and neck cancer: influence on nutritional status, utilization rate and complications. Int J Clin Pract 2019;73:e13405. (Pubmed-Link)

Hess AK, Jöhrens K, Zakarneh A, Balermpas P, von der Grün J, Rödel C, Weichert W, Hummel M, Keilholz U, Budach V, Tinhofer I.  Characterization of the Tumor Immune Micromilieu and its Interference with Outcome After Concurrent Chemoradiation in Patients with Oropharyngeal Carcinomas. Oncoimmunology 2019;8:1614858. (Pubmed-Link).

Hess J, Unger K, Maihoefer C, Schüttrumpf L, Wintergerst L, Heider T, Weber P, Marschner S, Braselmann H, Samaga D, Kuger S, Pflugradt U, Baumeister P, Walch A, Woischke C, Kirchner T, Werner M, Werner K, Baumann M, Budach V, Combs SE, Debus J, Grosu AL, Krause M, Linge A, Rödel C, Stuschke M, Zips D, Zitzelsberger HF, Ganswindt U, Henke M, Belka C. A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV-infection. Clin Cancer Res 2019;25:1505-1516. (Pubmed-Link)

Hoey C, Ahmed M, Fotouhi Ghiam A, Vesprini D, Huang X, Commisso K, Commisso A, Ray J, Fokas E, Loblaw DA, He HH, Liu SK. Circulating miRNAs as non-invasive biomarkers to predict aggressive prostate cancer after radical prostatectomy. J Transl Med 2019;17:173. (Pubmed-Link).

Hörner-Rieber JH, Bernhardt D, Blanck O, Duma M, Eich H, Gerum S, Gikka E, Hass P, Henkenberens C, Herold HU, Hildebrandt G, Imhoff D, Kahl H, Janssen S, Jurianz K, Krempien R, Lautenschläger SF, Lohaus F, Mueller AC, Petersen C, Sackerer I, Scafa D, Schrade E,  Uhlmann L, Wittig A, Guckenberger M. Long-term follow-up and patterns of recurrence of oligometastatic NSCLC patients treated with pulmonary SBRT. Clin Lung Cancer 2019;20:e667-e677. (Pubmed-Link).

Kashihara T, Murakami N, Tselis N, Kobayashi K, Tsuchida K, Shima S, Masui K, Yoshida K, Takahashi K, Inaba K, Umezawa R, Igaki H, Ito Y, Kato T, Uno T, Itami J. Hyaluronate gel injection for rectum dose reduction in gynecologic high-dose-rate brachytherapy: initial Japanese experience. J Radiat Res 2019;60:501-508. (Pubmed-Link).

Klement RJ, Abbasi-Senger N, Adebahr S, Alheid H ,Allgaeuer M, Becker G, Blanck O, Boda-Heggemann J, Brunner T, Duma M, Eble MJ, Ernst I, Gerum S, Habermehl D, Hass P, Henkenberens C, Hildebrandt G, Imhoff D, Kahl H, Klass ND, Krempien R, Lewitzki V, Lohaus F, Ostheimer C, Papachristofilou A, Petersen C, Rieber J, Schneider T, Schrade E, Semrau R, Wachter S, Wittig A, Guckenberger M, Andratschk A. The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases. BMC Cancer 2019;19:173. (Pubmed-Link)

Lang BM, Balermpas P, Bauer A, Blum A, Brölsch GF, Dirschka T, Follmann M, Frank J, Frerich B, Fritz K, Hauschild A, Heindl LM, Howaldt HP, Ihrler S, Kakkassery V, Klumpp B, Krause-Bergmann A, Löser C, Meissner M, Sachse MM, Schlaak M, Schön MP, Tischendorf L, Tronnier M, Vordermark D, Welzel J, Weichenthal M, Wiegand S, Kaufmann R, Grabbe S. S2k Guidelines for Cutaneous Basal Cell Carcinoma - Part 1: Epidemiology, Genetics and Diagnosis . J Dtsch Dermatol Ges 2019;17:94-103. (Pubmed-Link)

Linder B, Wehle A, Bonn F, Hehlgans S, Dikic I, Rödel F. Seifert V, Kögel D. Arsenic Trioxid and (-)-Gossypol synergistically target glioma stem-like cells via Inhibition of Hedgehog and Notch signaling. Cancers 2019:11:350. (Pubmed-Link)

Martin D, Rödel F, Balermpas P, Winkelmann R, Fokas E, Rödel C. C-reactive protein-to-albumin ratio as prognostic marker for anal squamous cell carcinoma treated with chemoradiotherapy. Front Oncol 2019;9:1200 (Pubmed-Link).

Martin D, Rödel C, Fokas E. Chemoradiotherapy for anal cancer: are we as good as we think? Strahlenther Onkol 2019;195:369-373. (Pubmed-Link)

Merten R, Ott O, Haderlein M, Bertz S, Hartmann A, Wullich B, Keck B, Kühn R, Rödel CM, Weiss C, Gall C, Uter W, Fietkau R. Long-Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High-Risk Bladder Cancer (Ta, Tis, T1, T2). Oncologist 2019;24:e1341-e1350. (Pubmed-Link)

Müller-Längle A, Lutz H, Hehlgans S, Rödel F, Rau K, Laube B. NMDA Receptor-mediated signaling pathways enhance radiation resistance, survival and migration in glioblastoma cells - a potential target for adjuvant radiotherapy. Cancers 2019;11:E50. (Pubmed-Link)

Murakami N, Shima S, Okuma K, Iijima K, Tselis N, Uematsu M, Takagawa Y, Kashihara T, Masui K, Yoshida K, Takahashi K, Inaba K, Igaki H, Nakayama Y, Itami J. Artificial ascites for organs at risk sparing in intrapelvic brachytherapy: a case report of recurrent uterine cervical carcinoma adjacent to the bowel. BJR Case Rep 2018;5:20180067. (Pubmed-Link)

Murakami N, Shima S, Kashihara T, Tselis N, Kato T, Takagawa Y, Masui K, Yoshida K, Takahashi K, Inaba K, Okuma K, Igaki H, Nakayama Y, Itami J. Hyaluronic gel injection into the vesicovaginal septum for high-dose-rate brachytherapy of uterine cervical cancer: an effective approach for bladder dose reduction. J Contemp Brachytherapy. 2019;11:1-7. (Pubmed-Link).

Murakami N, Kobayashi K, Shima S, Tsuchida K, Kashihara T, Tselis N, Umezawa R, Takahashi K, Inaba K, Ito Y, Igaki H, Nakayama Y, Masui K, Yoshida K, Kato T, Itami J A hybrid technique of intracavitary and interstitial brachytherapy for locally advanced cervical cancer: initial outcomes of a single-institute experience. BMC Cancer 2019;19:221. (Pubmed-Link)

Ott OJ, Micke O, Mücke R, Niewald M, Rödel F, Schäfer U, Seegenschmiedt MH, Arenas M, Frey B, Gaipl US. Low-dose radiotherapy: Mayday, mayday, we've been hit! Strahlenther Onkol 2019;195:285-288. (Pubmed-Link).

Raab M, Sanhaji M, Zhou S, Rödel F, El-Balat A, Becker S, Strebhardt K. Blocking mitotic exit of ovarian cancer cells by pharmaceutical inhibition of the Anaphase-Promoting Complex reduces chromosomal instability. Neoplasia 2019;21:363-375. (Pubmed-Link).

Rödel F, Martin D, Balermpas P, Wieland U, Winkelmann R, Riekmann T, Falk S, Rödel C, Fokas E. Modulation of radiation sensitivity and antitumor immunity by viral pathogenic factors: Implications for radio-immunotherapy. Biochim Biophys Acta Rev Cancer  2019;1871:126-137. (Pubmed-Link).

Stera S, Balermpas P, Blanck O, Wolff R, Wurster S, Baumann R, Szücs M, Loutfi-Krauss B, Wilhelm MS, Seifert V, Rades D, Rödel C, Dunst J, Hildebrandtg,  Arnold, A, Meissner M, Kähler, KC. Stereotactic radiosurgery combined with immune checkpoint inhibitors or kinase inhibitors for patients with multiple brain metastases of malignant melanoma. Melanoma Research2019;29:187-195. (Pubmed-Link).

Tselis N, Chatzikonstantinou G. Treating the Chameleon: Radiotherapy in the management of Renal Cell Cancer. Clin Transl Radiat Oncol 2019;16:7-14. (Pubmed-Link)

Von der Grün J, Köhn J, Loutfi-Krauss B, Blanck O, Rödel C, Balermpas P. Second infield re-irradiation with a resulting cumulative equivalent dose (EQD2max ) of >180 Gy for patients with recurrent head and neck cancer. Head Neck 2019;41:E48-E54. (Pubmed-Link)

Von der Grün J, Winkelmann R, Meissner  M, Wieland U, Silling S, Martin D, Fokas E, Rödel C, Rödel F, Balermpas P. Merkel cell polyoma viral load and CD8+ lymphocyte infiltration predict overall survival in patients with Merkel cell carcinoma. Front Oncol 2019;9:20. (Pubmed-Link)

Von der Grün J, Rödel F, Fokas E, Guckenberger M, Rödel C, Brandts C, Balermpas P. Targeted therapies and immune-checkpoint inhibition in head and neck squamous cell carcinoma: Where do we stand and where to go. Cancers 2019;11:472. (Pubmed-Link)

Voss M, Batarfi A, Steidl E, Wagner M, Forster MT, Steinbach JP, Rödel CM, Bojunga J, Ronellenfitsch MW. Adrenal Insufficiency in Patients with Corticosteroid-Refractory Cerebral Radiation Necrosis Treated with Bevacizumab. J Clin Med 2019;8:pii E1608. (Pubmed-LInk)

Voss M, Franz K, Steinbach JP, Fokas E, Forster MT, Filipski K, Hattingen E, Wagner M, Breuer S. Contrast enhancing spots as a new pattern of late onset pseudoprogression in glioma patients. J Neurooncol 2019;142:161-169. (Pubmed-Link)

Wunderlich R, Rühle P, Deloch L, Rödel F, Fietkau R, Gaipl U, Frey B. Ionizing radiation reduces the capacity of activated macrophages to induce T-cell proliferation, but does not trigger dendritic cell-mediated non targeted effects. Int J Radiation Biol 2019;95:33-43. (Pubmed-Link)

Yoshida K, Kotsuma T, Akiyama H, Yamazaki H, Takenaka T, Masui K, Tsujimoto Y, Murakami N, Uesugi Y, Shimbo T, Yoshikawa N, Yoshioka H, Nakata M, Arika T, Takaoka Y, Tanaka E, Tselis N. A new implant device to prevent edema-associated underdosage in high-dose-rate interstitial brachytherapy of mobile tongue cancer. J Contemp Brachytherapy. 2019;11(6):573-578 (Pubmed_Link).